23andMe (ME) Competitors $0.50 -0.27 (-35.32%) Closing price 03/28/2025Extended Trading$0.50 0.00 (0.00%) As of 03/28/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ME vs. MDCX, CTOR, IMAB, PMVP, IKNA, VTVT, IMRX, ICCC, VNRX, and APLTShould you be buying 23andMe stock or one of its competitors? The main competitors of 23andMe include Medicus Pharma (MDCX), Citius Oncology (CTOR), I-Mab (IMAB), PMV Pharmaceuticals (PMVP), Ikena Oncology (IKNA), vTv Therapeutics (VTVT), Immuneering (IMRX), ImmuCell (ICCC), VolitionRx (VNRX), and Applied Therapeutics (APLT). These companies are all part of the "pharmaceutical products" industry. 23andMe vs. Medicus Pharma Citius Oncology I-Mab PMV Pharmaceuticals Ikena Oncology vTv Therapeutics Immuneering ImmuCell VolitionRx Applied Therapeutics Medicus Pharma (NASDAQ:MDCX) and 23andMe (NASDAQ:ME) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, valuation, community ranking, analyst recommendations, earnings, institutional ownership, risk, dividends and media sentiment. Is MDCX or ME more profitable? Medicus Pharma has a net margin of 0.00% compared to 23andMe's net margin of -183.39%. Medicus Pharma's return on equity of 0.00% beat 23andMe's return on equity.Company Net Margins Return on Equity Return on Assets Medicus PharmaN/A N/A N/A 23andMe -183.39%-170.07%-62.13% Do analysts rate MDCX or ME? Medicus Pharma currently has a consensus target price of $12.00, suggesting a potential upside of 200.00%. Given Medicus Pharma's stronger consensus rating and higher possible upside, equities analysts plainly believe Medicus Pharma is more favorable than 23andMe.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Medicus Pharma 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 2 Strong Buy rating(s) 3.5023andMe 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Does the MarketBeat Community prefer MDCX or ME? 23andMe received 8 more outperform votes than Medicus Pharma when rated by MarketBeat users. However, 100.00% of users gave Medicus Pharma an outperform vote while only 46.15% of users gave 23andMe an outperform vote. CompanyUnderperformOutperformMedicus PharmaOutperform Votes4100.00% Underperform VotesNo Votes23andMeOutperform Votes1246.15% Underperform Votes1453.85% Do insiders and institutionals hold more shares of MDCX or ME? 36.1% of 23andMe shares are held by institutional investors. 26.3% of 23andMe shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Which has preferable valuation and earnings, MDCX or ME? Medicus Pharma has higher earnings, but lower revenue than 23andMe. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMedicus PharmaN/AN/AN/AN/AN/A23andMe$208.78M0.06-$666.70M-$15.45-0.03 Does the media prefer MDCX or ME? In the previous week, Medicus Pharma had 4 more articles in the media than 23andMe. MarketBeat recorded 12 mentions for Medicus Pharma and 8 mentions for 23andMe. Medicus Pharma's average media sentiment score of 0.98 beat 23andMe's score of -0.20 indicating that Medicus Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Medicus Pharma 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive 23andMe 0 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryMedicus Pharma beats 23andMe on 10 of the 14 factors compared between the two stocks. Get 23andMe News Delivered to You Automatically Sign up to receive the latest news and ratings for ME and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ME vs. The Competition Export to ExcelMetric23andMePharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$13.36M$6.44B$5.29B$7.35BDividend YieldN/A3.25%5.12%4.31%P/E Ratio-0.036.8821.7117.77Price / Sales0.06231.36379.3997.68Price / Cash0.9365.6738.2234.64Price / Book0.215.916.443.98Net Income-$666.70M$142.72M$3.21B$247.44M7 Day PerformanceN/A7.98%5.24%4.44%1 Month Performance-75.10%-13.91%-9.49%-7.73%1 Year Performance-93.01%-9.98%11.01%1.28% 23andMe Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ME23andMe0.3795 of 5 stars$0.50-35.3%N/A-93.0%$13.36M$208.78M-0.03770Gap DownHigh Trading VolumeMDCXMedicus PharmaN/A$3.84+6.1%$10.00+160.4%N/A$51.51MN/A0.00N/AAnalyst ForecastGap UpCTORCitius OncologyN/A$0.72+3.9%$3.00+318.5%N/A$51.30MN/A0.00N/AGap UpIMABI-Mab3.099 of 5 stars$0.62-8.8%$5.50+787.1%-53.0%$50.53M$3.27M0.00380Short Interest ↓Gap UpHigh Trading VolumePMVPPMV Pharmaceuticals2.342 of 5 stars$0.96-4.0%$5.50+472.9%-36.6%$49.86MN/A-0.9650Gap DownIKNAIkena Oncology3.0829 of 5 stars$1.03-8.8%$3.00+191.3%-10.5%$49.71M$659,000.00-0.8470Short Interest ↓Gap DownVTVTvTv Therapeutics2.2331 of 5 stars$15.35-5.6%$35.00+128.0%-18.4%$48.97M$1.02M-3.399Analyst ForecastShort Interest ↓IMRXImmuneering3.3219 of 5 stars$1.35-4.3%$12.50+825.9%-31.7%$48.45M$320,000.00-0.6960Short Interest ↓Gap DownICCCImmuCell0.0937 of 5 stars$5.38+0.4%N/A+8.9%$48.33M$26.49M-10.7670VNRXVolitionRx1.9679 of 5 stars$0.50-6.1%$3.75+650.2%-18.3%$48.26M$1.23M-1.3980APLTApplied Therapeutics3.822 of 5 stars$0.41-5.7%$6.10+1,387.8%-93.1%$47.71M$-212,000.00-0.2530Earnings ReportGap Up Related Companies and Tools Related Companies MDCX Competitors CTOR Competitors IMAB Competitors PMVP Competitors IKNA Competitors VTVT Competitors IMRX Competitors ICCC Competitors VNRX Competitors APLT Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ME) was last updated on 4/18/2025 by MarketBeat.com Staff From Our PartnersElon Reveals Why There Soon Won’t Be Any Money For Social SecurityElon Musk's Near-Death Experience Sparks Dire Warning for Americans After cheating death twice—once in a te...Colonial Metals | Sponsored🥾⛏️👷♂️ What I Learned From Numerous Mine Visits...Twenty years ago, I made a decision that changed my life. Instead of sitting behind a desk analyzing mining...Golden Portfolio | SponsoredClaim Your FREE Protection GuideIn the final days of his first term, Trump quietly left open an "off the books" wealth-protection loophole hid...American Alternative | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredHow War with China Could Start in 128 DaysThe clock is ticking. Those who aren't prepared could lose everything. I've identified 43 investments we...Behind the Markets | SponsoredMy prediction is coming trueWe've developed a surprisingly effective way to see which stocks could double during massive shake-ups, by usi...InvestorPlace | SponsoredThe Crypto Market is About to Change LivesI've discovered something so significant about the 2025 crypto market that I had to put everything else aside ...Crypto 101 Media | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding 23andMe Holding Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share 23andMe With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ME Stock Free ME Stock Alerts